Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
- Previous Close
219.10 - Open
221.45 - Bid 217.65 x --
- Ask --
- Day's Range
218.00 - 223.80 - 52 Week Range
109.42 - 328.02 - Volume
4,777 - Avg. Volume
19,305 - Market Cap (intraday)
14.594B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
23.09 - EPS (TTM)
9.51 - Earnings Date Aug 5, 2025 - Aug 9, 2025
- Forward Dividend & Yield 2.00 (0.91%)
- Ex-Dividend Date Sep 6, 2024
- 1y Target Est
--
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.
www.jagsonpal.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: JAGSNPHARM.BO
View MorePerformance Overview: JAGSNPHARM.BO
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JAGSNPHARM.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JAGSNPHARM.BO
View MoreValuation Measures
Market Cap
14.56B
Enterprise Value
13.88B
Trailing P/E
23.06
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.73
Price/Book (mrq)
7.39
Enterprise Value/Revenue
5.47
Enterprise Value/EBITDA
19.07
Financial Highlights
Profitability and Income Statement
Profit Margin
20.60%
Return on Assets (ttm)
10.84%
Return on Equity (ttm)
25.91%
Revenue (ttm)
2.69B
Net Income Avi to Common (ttm)
553.61M
Diluted EPS (ttm)
9.51
Balance Sheet and Cash Flow
Total Cash (mrq)
1.29B
Total Debt/Equity (mrq)
3.85%
Levered Free Cash Flow (ttm)
662.37M